South Korea's Green Cross seeks phase 2 trials of Covid-19 plasma drug

SEOUL - South Korea's Green Cross Corp has sought regulatory approval for Phase II trials of an experimental Covid-19 blood plasma treatment drug, the company said on Wednesday , sending its shares up nearly 10 per cent.

Green Cross said the clinical trial would review the safety and efficacy of the drug in 60 domestic patients in five hospitals. Its intravenously administered medicine, GC5131A, includes hyperimmune immunoglobins produced from processed antibodies in the plasma of recovered coronavirus patients. In May, it joined several firms working on plasma-based therapies to develop a treatment for Covid-19 patients.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

North Korea steps up coronavirus prevention after first possible infectionSEOUL (REUTERS) - North Korea introduced tougher prevention measures against the novel coronavirus on Tuesday (July 28), state media reported, after it locked down the border town of Kaesong to tackle what could be its first publicly confirmed case of the respiratory disease.. Read more at straitstimes.com.
Source: The Straits Times - 🏆 8. / 63 Read more »

North Korea steps up coronavirus prevention after first possible COVID-19 infectionNorth Korea introduced tougher prevention measures against the novel coronavirus on Tuesday, state media reported, after it locked down the border ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »